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Smary The contribution of host-derived growth factors to tumour growth in vivo was studied using the
transplantable murine mammary carcinoma, MTI, grown in syngeneic mice. Promotion of growth of the
mammary carcinoma by a factor(s) from the host was cvient in experiments in which the carci cels
were inoculated intaperitoneally. In this environment, tumours develop as multiple sold noduks, each
probably arisng from an individual cell or a small cluster of cels Tumour growth was found to occur in the
peritoneal cavity following inoculation of 10' cells, but an inoculum of as few as ten cells grew if a
leucocyte-rich exudate had first been induced. To determine which host-derived growth factors might con-
trnbute to growth of MT1, extracts of the tumour were first examined for growth factor activity. Fractionation
of tumour extracts by either ion-exchange chromatography or gel filtration revealed several peaks ofmitogenic
activity, but none of this could be attributed to epidermal growth factor (EGF). Accordingly, an anti-EGF
antibody was tested as a putative inhibitor of tumour growth as any effect of this antibody could be ascribed
to removal of EGF derived from the host The antibody was found to have potent anti-tumour activity when
tested aganst MT1 tumours that had been inoculated into the peritoneal cavity. In contrast, the antibody had
little effect on growth of the discrete tumour mass which formed when MTI was translanted subcutaneously.
The results suggest that host-derived EGF contributes to establshment of microcolonies of MT1 carcnoma
within the peritoneal cavity. This may be dimctly, by proding growth factors to supplment those produced
by the tumour until it reaches a certain critical mass to sustain autocrine growth, or indirectly, by affecting the
production of other growth-stimulatory factors or cytokines.
When grown in tissue culture, malignant cells generally
require less exogenously added growth factors than their
normal counterparts. This has led to the autocrine
hypothesis, which proposes that cancer cells are able to
sustain their own growth by synthesis of growth-stimulatory
factors for which they possess appropriate cell-surface recep-
tors (Sporn & Todaro, 1980). Although there is now con-
siderable evidence in support of this hypothesis, it is also
apparent that the autocrine growth factors produced by
cancer cells are not always suffiient to sustain maximal
growth. Thus, in tissue culture, exogenously added growth
factors such as epidemal growth factor (EGF) have been
shown to stimulate growth ofprimary and metastatic tumour
cells (Singletary et al., 1989). Similarly, in vivo, studies on the
sites of growth of tumours derived from blood-borne car-
cinoma or sarcoma cells have suggested that host-derived
growth factors could be necessary for growth to occur from
isolated (or small clusters of) tumour cells (Murphy et al.,
1988). The requirement for these factors may arise because
diffuision lowers the effective local concentration of tumour-
derived growth factors, which may then be insufficient to
induce division of the isolated cell (Alexander, 1987). This
problem of diffusion diminishes as the number of cells in
close proximity increases (i.e. as the tumour grows). For an
isolated cell to develop into a tumour, it is postulated that
autocrine growth factor(s) need to be supplemented by host-
derived factors.
Several lines of evidence have indicated an in vivo role for
EGF in tumour development and progression. Thus, EGF
has been found to enhance spontaneous mammary tumori-
genesis (Kurachi et al., 1985) and to promote implantation
and/or growth of spontaneous mammary tumours in mice
(Tsutsumi et al., 1987; Inui et al., 1989). In these studies,
direct evidence for a role of host-derived EGF was obtained
by use of mice in which the amount of EGF in blood had
been reduced to low levels by surgical removal of the salivary
gland (sialoadenectomy). In such mice, the growth of the
tumour was reduced and the effects ofsialoadenectomy could
be reversed by the administration of EGF. In studies using a
rat rhabdomyosarcoma, cell proliferation was stimulated by
EGF and a role for EGF was further demonstrated in pro-
motion of lung and lymphatic micrometastases (Breillout et
al., 1989). Growth of human A431 tumour cells, which ex-
press an unusually high number of EGF receptors in athymic
mice, has also been shown to be stimulated by EGF, even
though this growth factor is growth inhibitory (at nM con-
centrations) for A431 cells cultured in vitro (Ginsburg &
Vonderhaar, 1985; Ozawa et al., 1987).
In the present study, the wansplantable murine mammary
carcinoma, MT1 (Barnett & Eccles, 1984), was grown in the
peritoneal cavity and used as a model for growth of isolated
cancer cells. This is an appropriate system to test the con-
tribution of host-derived EGF to growth because, as will be
shown, MT1 does not synthesise any detectable EGF and its
growth in vivo is promoted by host factors. The first of these
investgations was reported at a meeting and published in an
abstract (Blackler et al., 1988).
Materials an mthod
Materials
Sheep anti-EGF IgG and rabbit anti-EGF IgG fractions were
prepared by ammonium sulphate precipitation and DEAE-
cellulose chromatography of sera from animals immunised
with murine EGF (EGF was a gift from P. Moore, CSIRO,
Australia). Transforming growth factor E (TGF-a) and all
tisue culture reagents were from Gibco BRL, UK.
Growth ofMT] in vivo and in vitro
MTI tumour was obtained from S. Eccles (Institute for
Cancer Research, Sutton, UK) and was routinly passaged in
syngeneic host CBA/Ca mice by subcutaneous transplanta-
tion of small tumour fragments or cell suspensions (Barnett
& Eccles, 1984).
In the experimental protocols described for in vivo growth
of MTI, tumour cell suspensions were first prepared by
disaggregation of finely chopped tumour fragments for
45 min in Hanks' balanced salt solution (HBSS) containing
0.5mgml-' dispas and 5 gmlg ' deoxyribonuclease (both
from Sigma). Cells were washed by centrifugation and cul-
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tured for 24-48 h in Dulbeco's minimal essential medium
containing 10% (v/v) fetal bovine sewrum 10 IU m1'penicil-
ln and lOgmlPl streptomycin (10% FBS/DMEM) before
translantation. The cultured cells which were adherent were
rekased from the plastic flask by trypsinisation. After
washing in HBSS, a viable cell count was determined by
trypan blue exclusion and appropriate dilutions of cells in
HBSS prepared for transplantation. Tumour growth within
the peritoneal cavity was monitored by palpation; animals
were killed either when tumour masses were clearly evident
or shortly before the animals became moribund following
UKCCCR guidelines.
For in vitro growth experiments, cell cultures were
prepared as described above and routinely aged in 10%
FBS/DMEM. The effect of EGF on growth of MTI in vitro
was tested in DMEM containing either FBS or newborn
bovine serm which had been depleted of cationic growth
factors (cNBS) by extraction for 2-4 h with Chelex 100
ion-exchange resin (100-200 mesh, BioRad Laboratories)
using 40g of resin equilibrated to pH7.4 per lOOml of
serum. After this treatment, the serm possessed minimal
mitogenic activity in the standad mitogenesis assay using
foreskin fibroblasts (see below). Cells (2.5 x 10) were seeded
in 25 cm2 fiasks in the p or absence of EGF (1 nM)
and the cell number in duplicate flasks determined at appro-
priate intervals.
Determination ofmacrophage number in peritoneal exudates
Macrophages present in peritoneal exudates were initially
identified as mononuclear cells which adhered to plastic in
serum-free medium. Control or pristane-treated animals were
killed and the peritoneal cavity lavaged with HBSS to obtain
cels present in the peritoneal exudate. The cells were
harvested and allowed to adhere to plastic tissue culture
dishes in serum-free DMEM for 24 h. After washing to
remove non-adherent cells, the cells were harvested and
counted. Approximately 85% of these mononuclear cells
stained with non-specific esterase and these cells were scored
as macrophages. The other 15% were T lymphocytes.
Mitogenic activity in cell-free extracts ofMT]
MTI tumour was homogenised in 1 M acetic acid containing
10 zgml'I aproinin, 10 g ml ' leupepti, 17 g ml I phenyl
methyl sulphonylfluoride (PMSF), 5 mM benzamidine,
5 tgml1l pepstatin A, I mM N-a-p-tosyl-L-lysine chloro-
methyl ketone (TLCK) and 1 mM N-tosyl-L-phenylalanine
chloromethyl betone (TPCK) and the extract clarified by
centrifugation at 100,000g for 1 h at 4C. The supernatant
was neutralised and dialysed against 25 mM Tris-HCl,
pH 7.4, before fractionation by fast protein liquid anion-
exchange chromatography (FPLC) using a Mono-Q column.
The column, which was equilibrated with 25 mM Tris-HCI,
pH 7.4, was loaded with 2.5 mg of protein and bound protein
eluted with a salt gradient from 0 to 0.5 M sodium chloride
over 20 ml. Fractions (1 ml) were collected into tubes con-
taining 100 ,Il of 1% BSA in phosphate-buffered saline (PBS)
containing IO IU ml'l penicillin and I0 gml' streptomycin
and assayed as described below.
To enable detection of the membrane-bound, precursor
form of EGF, MTI tumour was homogenised in ice-cold
20 mM HEPES buffer containing 0.1 M sodium chloride and
protease inhibitors as above. After adjusting the protein con-
centration of the extract to 12 mgml-, CHAPS detergent
was added to a final concentration of 10mM and the extract
left on ice for 1 h before centrifugation at 100,000 g for 1 h.
The supernatant was analysed by FPLC using a Superose
12 gel filtration column equilibrated with 20 mM HEPES
buffer, pH 7.4, containing 0.1 M sodium chloride and 0.1%
(w/v) CHAPS. Fractions (1 ml) were collected as above. The
positions where 6kIDa EGF and its 150 kDa precursor were
detected when similar extracts of mouse kidney were
analysed by this method are indicated in Figure lb.
Aliquots of fractions (40gil) from both separation methods
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Fugwe 1 Mitogenic activity in extracts of MTI tumour. MTI
tumour tissue was extracted and analysed by column chromato-
graphy as described in the Materials and methods section. The
figure shows the profile of mitogenic activity (V) obtained when
a, an acidic tumour extract was analysed by anion-exchange
chromatography and b, a detergent extract was analysed by gel
filtration. The presence or absence of EGF in individual fractions
was determined by the ability of sheep anti-EGF IgG (0) or
sheep anti-EGF receptor IgG (0) to neutralise the observed
mitogenic activity. The short and long arrows indicate the
expected positions of EGF and its precursor respectively.
were assayed for mitogenic activity and immunoreactive EGF
as described below. Control experiments established that, at
the dilution used, the salt or detergent concentrations present
in the individual fractions did not significantly affect the
mitogenic response of the cells to EGF.
Mitogenesis assay using density-arrestedfibroblasts
Mitogenic activity was determined in a standard assay
(Carpenter & Cohen, 1976) using confluent and quiescent
human foreskin fibroblasts which had been obtained from a
surgically removed foreskin and which were maintained in
short-term culture for up to 20 passages; the assay was
modified by use of ['2I]5'-iododeoxyuridine instead of
[3Hjthymidine to facilitate sample processing for counting.
For assay, cells were seeded at 2.5 x 0I cells ml-' in 96-well
trays and grown to confluence. After rendering the cells
quiescent by incubation in 1% FBS/DMEM for 48 h, test
substances (antibody, EGF, column fractions) were added to
cells in serum-free DMEM-PBS (1:1) containing 1% bovine
serum albumin, 4pg ml-' insulin, 240 tg ml-' transferrin,
25 mM HEPES buffer, pH 7.4. Stimulation of DNA synthesis
was assessed 23 h later by pulsing the cells for 2 h with
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['UI5'-iododeoxyyuridine (92 kBq ml-', 74 TBq mmol-') con-
taining 5 jim 5-fluor-2'-deoxyuridine (FUdR). Acid-insoluble
radioactivity was determnined by gamma counting.
Enzyme-linked immunosorbent assays (ELISAs) for anti-EGF
IgG and EGF
Sheep anti-EGF IgG was measured in sera of treated mice
using EGF (1.6 pmol per well) which was immobilised onto
the wells of an ELISA tray by incubation overnight in buffer
containing 35 mM sodium bicarbonate, 15 mM sodium car-
bonate and 0.2% sodium azide, pH 9.6. After blocking
residual binding sites using 1% (w/v) bovine serum albumin
in 50 mM Tris-HCI, 145 mM sodium chloride, 0.05% (vlv)
Tween-20, pH 7.4 (TB/BSA buffer), serum samples were
diluted in the same buffer (1:5 and four serial doubling
dilutions) and applied to the wells. Following a 2 h incuba-
tion at 3TC, bound antibody was detected, after washing, by
incubating with 100IgI per well rabbit anti-sheep immuno-
globulins conjugated to horseradish peroxidase (diluted
1:1,000) for 1 h at 37°C before visualisation using 0.01%
hydrogen peroxide in 0.1 M sodium acetate buffer containing
0.015 mM 3,3',5,5'-tetramethylbenzidine dihydrochloride
(TMB) as chromogen. The colour reaction was terminated by
acidification (50 1j of 2 M sulphuric acid per well) and the
absorbance of each well was recorded at 450 nm. Sheep
anti-EGF was quantitated by reference to a standard curve
generated by dilution of known quantities of the antibody
(0-25 jig ml- '). The initial dilution of antibody was prepared
in sera obtained from untreated mice.
EGF was measured in urine and serum of mice using a
competitive binding immunoassay in which EGF contained
in samples competed with immobilised EGF for binding to
an anti-EGF antibody. Sera or urine samples were diluted in
TB/BSA buffer (1:1 or 1:80 respectively, and four serial
doubling dilutions) in an ELISA tray and then mixed with an
equal volume of rabbit anti-EGF IgG (1 jigml-'). After
incubation overnight at 4C, 1001il aliquots were transferred
to a second ELISA tray to which EGF has been coupled as
above. Following a 2 h incubation, antibody bound to the
ELISA tray was detected using swine anti-rabbit immuno-
globulins conjugated to horseradish peroxidase following the
procedure outlined above. EGF contained in the samples was
estimated by reference to a standard curve generated using
mouse EGF (0-8 nM).
EGF was measured in column fractions using a sandwich
ELISA which was approximately three times more sensitive
than the competitive binding assay described above. In this
assay, EGF was trapped by sheep anti-EGF IgG (1.5 jig)
coupled to the wells of an ELISA tray. Bound EGF was
detected by rabbit anti-EGF IgG (0.5#jgperwell) followed
by a peroxidase-conjugated anti-rabbit IgG with colorimetric
detection as above. EGF in samples was estimated by
reference to a standard curve generated using mouse EGF
(0-3.0 nM).
Immunocytochemical staining ofmouse kidney
Frozen sections of kidney (approximately 5 jm thick) were
fixed in dry acetone and processed using standard immuno-
histochemical techniques. Primary sheep anti-EGF IgG
applied to tissue sections or sheep anti-EGF IgG immune
complexes localised in damaged kidneys of treated mice were
detected using an anti-sheep immunoglobulin-peroxidase
conjugate which was visualised using hydrogen peroxide -
3,3'-diaminobenzidine (DAB) as chromogen.
Results
Growth ofMT] carcinoma cells in the peritoneal cavity and
the effect ofpristane on growth
Following intraperitoneal injection, MT1 cells grew as mul-
tiple solid tumour nodules. The initial site of growth was the
greater omentum, followed by the mesentery and fat. The
diaphragm and muscle wall were colonised as a secondary
event. The pattern of growth of the MT1 tumour cells sug-
gested that the tumour deposits had originally arisen from
growth of a single cell or a small cluster of cells and that the
initial establishment of the tumour cell colony might thus
mimic the growth of a metastatic cancer cell after it had left
the circulation and finally lodged at a site distant from the
primary tumour.
The number of tumour cells needed to induce solid
tumours was greatly reduced in the mice injected with the
mineral oil pristane, which induces a macrophage-rich ascites.
Table I shows a comparison of the incidence of tumour take
in relation to the number of cells injected into control mice
or mice which had been injected with 0.5 ml of pristane i.p.
14 days prior to inoculation of the carcinoma cells. Whereas
tumour growth was observed when 102 to 103 tumour cells
were inoculated into control mice, tumour growth was
observed using an inoculum containing only ten cells in the
pristane-treated mice. Our observation of tumour growth
using such a low inoculum further supports the concept that
growth within the peritoneal cavity can be considered as a
model for growth of isolated cancer cells. Optimum promo-
tion of growth was obtained when 0.5 ml of pristane was
injected i.p. 14 days prior to the inoculation of carcinoma
cells. In contrast, no sensitisation was observed when 102
tumour cells were inoculated into the peritoneal cavity 3 or
30 days after pristane treatment. At day 14, pristane was
found to cause an enlargement of the omentum and in-
creased cellularity of the omentum and mesentery. The
number of cells that could be retrieved from the peritoneal
cavity by lavage was also increased; the peritoneal exudate
was found to contain approximately 2.2 x 107 macrophages
(Table II). These effects of pristane were not observed at 3 or
30 days. These results suggest that pristane enhanced estab-
lishment and growth of MTI cells in the peritoneal cavity by
induction of an inflammatory infiltrate.
Absence ofEGF in extracts ofMTJ tunours
As EGF has been implicated in tumour development and
progression, this growth factor was selected as a possible
candidate molecule produced by the host which might be
T.ble I Effect of pristane on the intraperitoneal growth of MTI
tumour
Tumour prevaknce
Number of cells injected Control Pristane treated
10 0/5 1/5; 4/5
102 1/5 5/5
103 3/5 5/5
i04 5/5 5/5
Mice were treated with pristane (0.5 ml of pristane i.p.) 14 days
prior to inoculation of tumour cells. Inocula containing log dilutions
of MT1 ells were injected into the peritoneal cavity offive untreated
or five pristane-treated mice. After 30 days, the aninals were killed
and tumour prevalence determined at autopsy.
Tae II Effect of time following pristane injection on sensitisation
of tumour take and number of macrophages in the peritoneal
exudate
Duration of pristane Twnour Macrophages detected in
sensitisation (days) prevalence peritoneal exudate
Control (no pristane) 1,5 0.4 x 106
3 0/5 1.2 x I06
14 515 2.2x 107
30 15 2.1x106
Two groups, each of five mice, were treated with 0.5 ml of pristane
i.p. for the times shown above. One group was then inoculated with
10 MT] cells and tumour prevaklnce determined 28 days later. The
other group was subjected to peritoneal lavage to determine the
number of cells present in the peritoneal exudate at the time of
inoculation. Macrophages were identified and counted as described
in the Materials and methods section.266 D.E. DAVIES et al.
responsible for the promotion of growth of MTI in the
peritoneal cavity. However, to be able to determine whether
EGF produced by the host contributed to proliferation of
MT1, it was necessary to establish that the tumour did not
produce this growth factor.
Initially, MT1 tumour tissue derived from subcutaneous
tumour implants was extracted into acid as previously de-
scribed (Koyama & Podolsky, 1989). Separation of this ex-
tract by FPLC Mono-Q anion-exchange chromatography
resulted in the detection of several peaks of mitogenic
activity, however none of this activity could be blocked by
anti-EGF IgG (Figure la), nor could immunoreactive EGF
be detected in crude extracts or the individual fractions (data
not shown).
As EGF is also synthesised as a high molecular weight
membrane-bound precursor which has been reported to be
biologically active (Mroczkowski et al., 1989), detergent ex-
tracts of MT1 tumour were also analysed to test if EGF
occurred in the tumour in this form. Conditions for the
extraction, partial purification by gel filtration and assay of
the 150 kDa membrane-bound EGF precursor were estab-
lshed using mouse kidney. Even though kidney contains
substantially lower levels of EGF than salivary glands, the
developed procedure enabled detection of both the precursor
and mature forms of EGF using both a sensitivie ELISA and
the mitogenic assay of growth-arrested human foreskin
fibroblasts (data not shown). Analysis of detergent extracts
of MTI tumours by this procedure yielded fractions which
demonstrated mitogenic activity in the standard assay; how-
ever, as found with the acidic extracts, the activity of these
fractions could not be blocked by anti-EGF antibody (Figure
lb), nor could immunoreactive EGF be detected by ELISA.
Moreover, the mitogenic activity was not blocked by an
antibody directed against the EGF receptor (EGFR) (Figure
lb), which blocks the mitogenic activity of both EGF and
TGF-a. The nature of the mitogenic activity found in the
extracts of MTI cells remains to be elucidated, but it was
neither EGF nor its membrane-bound high molecular weight
precursor. Given the lower limit of detection of our assays,
we calculate that MTI tumour can only contain less than
I pmol of EGF per g wet weight of tumour tissue.
Effect ofEGFon growth ofMTJ cells in vitro
Having established the absence of EGF in MTI tumours, the
effect of EGF on in vitro growth of MTI cells was investi-
gated. MTI cells, obtained by proteolytic disaggregation
from the tumour, were readily established in vitro in 10%
FBS/DMEM. The cells were adherent and exhibited cuboidal
and fusiform morphologies as previously reported (Barnett &
Eccles, 1984). The MTI cells could not be grown in serum-
free medium even when this had been supplemented with
insulin and transferrin, but could be grown in medium con-
taining serum which had been depleted of cationic growth
factors such as platelet-derived growth factor (PDGF) by
passage over a cation-exchange resin (cNBS). When MTI
cells were cultured in 2% cNBS/DMEM, 1 nM EGF stimu-
lated growth as evidenced by an increase in cell number
(Figure 2). The most marked effect of EGF was to reduce the
lag phase preceding growth; once the cells had established
growth, EGF provided no additional stimulus.
Inhibition ofmitogenic activity ofEGFby anti-EGF IgG and
correlation with serwn sheep anti-EGF IgG levels
To determine whether host-derived EGF contributed to
establishment of MT] tumours grown in the peritoneal
cavity, the effect of an anti-EGF IgG on tumour growth was
determined. The IgG preparation used in the investigations
described below was first tested for its ability to inhibit
EGF-induced DNA synthesis. The mitogenic action of EGF
was assayed by the standard procedure of initiating DNA
synthesis in growth-arrested cultures of human foreskin
fibroblasts. Figure 3 shows the degree of inhibition produced
by increasing doses of the antibody on the stimulation of
DNA synthesis induced by 1 riM EGF. Inhibition was com-
plete using immune IgG at a concentration of lOggml-',
whereas similar doses of control, non-immune, IgG had no
effect on EGF-stimulated DNA synthesis. The anti-EGF
antibody produced no inhibition of mitogenesis induced by
TGF-x (see Figure 3), even though these two ligands are
structurally homologous and both bind to the EGF receptor.
Table III shows the range of concentrations of EGF over
which a dose of 380pgml-' antibody is effective.
The concentration of sheep anti-EGF IgG in serum of
mice treated with a single i.p. injection of 2.5 mg antibody
was assessed by ELISA. The level of sheep anti-EGF IgG
attained a peak serum level in vivo of 718pg ml-' within I h
of administration and decayed to 230-240pgmnl' over 4-5
days (Table IV). Figure 3 shows that, in an in vitro assay, as
little as l10pgml-' antibody is capable of inhibiting com-
pletely the mitogenic activity of 1 nM EGF, and Table III
shows that, at 380pgml', the antibody is able to inhibit
E
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Fge 2 Effect of EGF on growth of MTI cells in vitro. MTI
cells were plated at 0.5 x 05cellsml-' in the presence (A) or
absence (A) of I nm EGF. At appropriate times, duplicate flasks
ofcells were harvested and viable cells determined by trypan blue
exclusion and counting. The results show the mean cell number
determined at each time point.
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Fugue 3 Inhibition of EGF-induced DNA synthesis by sheep
anti-EGF IgG. Stimulation of DNA synthesis in confluent and
quiescent human foreskin fibroblasts was measured in response to
I nm EGF (0) or TGF-a (A) as described in the Materials and
methods section. The figure shows the effect of the presence of
increasn concentrations of sheep anti-EGF IgG (open symbols)
or IgG prepared from an unimmunised sheep (closed symbols) on
this stimulation. The results are presntative of two individual
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TAb m Inhibition of EGF-indumd DNA synthesis in human
foreskin fibroblasts by sheep anti-EGF IgG
[EGFJ (ni) Inhibition of DNA synthesis (%)
2 88
8 85
32 80
128 24
512 0
2048 -3
The ability ofa fixed dose ofsheep anti-EGF IgG (380jigml1') to
inhibit DNA synthesis in response to i sin doses of EGF was
assayed using quiescent human foreskin fibroblasts in a gandard
mitogenesis assay as described in the Materials and methods section.
Results are exp as percentage inhibition of DNA synthesis
when compared with duplicate wells of cells treated with each dose
of EGF alone. In the absence of antibody, 2 nM EGF produced
maximal stimulation of DNA synthesis, i.e. the doses of EGF tested
were all in excess of that required to saturate the system.
Table IV Serum antibody and urinary EGF kvels in mice treated
with a single dose of sheep anti-EGF IgG
Tim after Sheep anti-EGF
admnistration IgG in serwn Urinay EGF
of antibod (h) (JLgmt') (jgml-')
0 - 4.4
1 718 4.7
6 640 15.4
18 384 14.1
24 272 9.4
50 240 17.1
105 234 15.3
Mice were treated with 2.5 mg of sheep anti-EGF IgG intraperi-
toneally. At each time point, three animal were kiled and serum
and urine colected and combined for determination of sheep anti-
EGF IgG and EGF recively, as described in the Mateials and
methods section.
Table V Effect of treatment with anti-EGF IgG on intraperitoneal
growth of MT1 cells
Tumour prevaknce
Control (five mice) Anti-EGF IgG (five mice)
Two + + Thre none
Thre + + + One+
One + +
Approximately 5 x 103 mammary carcinoma cells were trans-
planted into the peritoneal cavity ofmice, which were then either left
untreated or treated with 2.5 mg of sheep anti-EGF intraperitoneally
three times per week, staring 2 days after tansplantaon After 29
days, aninmls were kiled and tumour burden assessed as follows: +,
<10 small nodule confined to omentum; + +, omentum exten-
sively involved, no spread; + + +, widespread involvement including
muscle wall.
concentrations of up to 32nM EGF; for comparison, the
serum level of EGF of untreated mice was less than the
lowest level which our ELISA allowed us to determine, which
was 0.12 nm. It is clear, therefore, that the circulating level of
antibody was greatly in excess of EGF in the circulation.
Treatment ofMT] carcinomafor 29 days with anti-EGF IgG
In a preliminary experiment to determine the effect of anti-
EGF IgG on growth of MT1, two groups, each of five mice,
were inoculated i.p. with 5 x 103 MT1 tumour cells; one
group was given 2.5 mg of sheep anti-EGF IgG i.p. on
alternate days starting 3 days after inoculation of tumour
cells and the second group was left untreated. On day 29 of
the experiment the first mouse in the control group was
becoming moribund and the experiment was terminated at
this time. All of the mice were killed and autopsied. The
findings are summarised in Table V and demonstrate that the
antibody exerted a pronounced growth-inhibitory effect.
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Flgwe 4 Anti-tumour effect of long-term treatment with sheep
anti-EGF IgG. Approximately 5 x 103 MTI tumour cells were
transplanted into the peritoneal cavity of mice, which were then
either left untreated ( _ ) or treated with 2.5 mg of non-immune
sheep IgG (1O ) or anti-EGF IgG (M) using the regimen
described in the legend to Table V. The chart shows the times at
which individual animals in each group were killed because of
tumour burden. Analysis of the data using Wilcoxon's rank
correlation test showed that there was a significant difference
between survival of either untreated or control IgG-treated
animals vs anti-EGF IgG-treated animals (P<0.05).
Anti-tmnour effect oflong-term treatment with anti-EGF IgG
Three groups of ten mice, inoculated with MT1 tumour cells
as in the preceding experiment, received either (a) no treat-
ment, (b) normal IgG from an unimmunised sheep or (c)
sheep anti-EGF IgG. Three days after inoculation of the
tumour cells, 2.5 mg of the immunoglobulins were injected
into the peritoneal cavity on alternate days for 4 weeks.
Unlike the preliminary experiment, survival of each indivi-
dual mouse was followed. The experiment was terminated
after 110 days when surviving animals were killed and autop-
sied. The outcome of the experiment is shown in Figure 4.
There was no significant difference in the rate of tumour
development between the groups receiving no treatment or
control IgG from a non-immunised sheep. In these two
groups, morbidity from tumour burden first occurred at days
30 and 32 respectively and eight out of ten animals had to be
killed as result of tumour growth by day 60. The remaining
two animals in both of the groups were alive and free of
tumours when killed 3 months later. In the group of mice
which received the anti-EGF IgG, three animals in the group
were killed between days 60 and 67 as a result of tumour
growth; the remaining seven animals had to be killed because
of their poor condition between days 83 and 95, but on
autopsy no tumour could be detected and morbidity was
found to be due to renal failure. Indeed, the kidneys were
extensively damaged in all ten mice in this group, including
the three that at autopsy contained some tumour.
Histochemical examination of the damaged kidneys
showed that the lesions were due to glomerular deposition of
immune complexes containing sheep IgG; no such immune
complex disease was found in mice that had received the
non-immune sheep IgG (results not shown). When normal
kidney sections were stained with the anti-EGF IgG, staining
was seen in the distal tubules which have previously been
found to be a site of EGF synthesis by in situ hybridisation
(Salido et al., 1989). These results suggest that the cause of
the kidney damage was not due to the reaction of the anti-
body with EGF produced in the kidneys, A this occurs at a
different site (i.e. the distal tubules), but rather from the
immune complex deposition in the glomeruli.26S D.E. DAVIES et al.
Although anti-EGF IgG treatment caused long-term
kidney damage, the antibody had noimmiate effect on the
production of EGF by the distal tubules in short-term
experiments in which output of EGF in the urine was
measured following a single i.p injection of 2.5 mg of
antibody. Table IV shows that anti-EGF IgG treatment did
not cause the amount of EGF in the urine over a 7 day
period to fall. Since in these animals antibody was present in
great excess, EGF in the urine is unlikely tobe derived to
any significant extent from EGF circulating in the blood or
extracellular tissue fluids. Unfortunately, no urine was taken
after prolonged antibody treatment which gave rise to the
lethal kidney lesions. Our results support the findings of
Mattila et al. (1988), who concluded that urinary EGF in
humans has a renal origin.
Response ofMTJ carcinoma cells growing subcutaneously
To compare the effect of anti-EGF IgG treatment on the
growth of MTI cells at a site other than the peritoneal
cavity, MTI cells were grown subcutaneously. The cell dose
needed to induce a tumour at a subcutaneous site ofinjection
was found to be much greater than that needed for tumour
growth intraperitoneally. Inoculation of 104 cells caused
tumours in two out of five mice, whereas inoculation of
5 x 10' cells caused tumours in five out of five mice. After
ten mice were inoculated with 5 x 10 cells, five were treated
with the anti-EGF antibody by the protocol used in the
preliminary (i.e. 29 day) treatment of tumours and five mice
were left untreated. Both treated and control groups had
100% tumour prevaklnce and there was no significnt differ-
ence in the size of the tumour in the control and treated
groups. The tumour weight was, on average, 0.45 g in the
control and 0.49 g in the treated group.
The present investigation has demonstrated that host-derived
factors can influence the growth of the MTI mammary car-
cinoma when transplanted into the peritoneal cavity. In this
environment the tumour grows as multiple solid nodules
which have probably arisen from individual cells. In this
respect, factors influencing the initial establishnt of MTI
tumour microcolonies may be similar to those that influence
the ability of a metastatic cancer cell to grow once it has left
the circulation and lodged at a distant site in the body. In
previous studies, it has been shown that blood-borne cancer
cells exhibit organ-seective tumour growth (Murphy et al.,
1988). Similarly, tumour outgrowth has been shown to occur
preferentially at sites of wound healing, and it has been
postulated that factors released by host cells into the
inflammatory wound environment to promote healing also
facilitate tumour growth (Skipper et a!., 1988). In the present
study, the growth-promoting properties of pristane correlated
with its ability to produce an inflammatory environment
within the peritoneal cavity, and here again enhanced tumour
take is likely to be due to direct or indirect effects of host-
derived growth factors or cytokines released at the
inflammatory site.
One of the factors found to contribute to tumour growth
was identified as EGF on the basis of the anti-tumour effect
of an anti-EGF antibody which only inhibits EGF and does
not cross-react with other growth factors such as TGF-a or
PDGF. As the MTI carcinoma was shown not to produce
any detectable EGF, the inhibition ofits growth by antibody
could not, therefore, be ascribed to interference of autocrine
growth stimulation. Although we cannot completely exclude
the possibility that the kidney damage caused by long-term
anti-EGF treatment accounted for the decreased tumour
growth, this seems unlikely as in the initial short-term experi-
ment in which animals were followed for up to 28 days no
evidence of kidney damage was evident at autopsy even
though tumour growth was reduced by the antibody treat-
ment.
EGF may have caused stimulation of growth of MT1
through a number of mechanism. One possibleinterpreta-
tion of our results is that host-derived EGF has a direct
effect on growth ofMT1 cells in vivo and that this gives them
aninitial growth advantage. At this time, when the tumour
cells are spread within the peritoneal cavity and isolated from
each other, diffusion of autocrine factors away from the cell
surface maylimit their availability and, similarly, availability
of membrane-bound factors would belimited only to cells in
direct contact This proposal is consistent with the observed
ability of EGF to reduce the time taken before establishment
of log phase growth of MT1 in vitro. Alternatively, a more
complex situation may exist whereby EGF exerts indirect
effects on growth of MT1. For example, depletion of host-
derived EGF may prevent induction of other growth factors
or cytokines which facilitate tumour growth or which are
responsible for induction of the inflammatory environment
In this context, it has been shown that EGF and TGF-a
regulate cytokine production by human thymic epithelial cells
(Le et al., 1991).
The host-derived EGF which promotes the growth of the
carcinoma cells may come from circulating EGF in the
blood, however the plasma concentration of EGF is ex-
tremely low. Since, as shown in TableI, growth ofMT1 cells
is geatly facilitated within a pentoneum enriched in
leucocytes as a result of prior stimulation by pristane, the
EGF involved may come from this source. Platelets contain a
high concentration of EGF which is rekased on clotting
(Nakamura et al., 1989; Hwang et al., 1992). Although
activated macrophages have been shown to synthesise TGF-x
(Madtes et al., 1988), whether they produce EGF has not
been cleary established. They do however, produce a related
form of EGF, namely heparin-binding EGF (Higashiyama et
al., 1991); cross-reactivity of our antibody with this ligand, or
with other EGF receptor ligands such as amphiregulin
(Shoyab et al., 1989), cannot be excluded until authentic
forms of the murine ligands are available. Alternatively, a
more complex paracrine mechanism may be operative where-
by growth factors (such as the colony-stimulating factors)
which are produced by macrophages ul-regulate expression
of EGF by fibroblasts or epithelial cells in the peritoneal
cavity and this is then available to promote growth of the
MTI tumour cells.
In contrast to the results obtained with MTI grown intra-
peritoneally, subcutaneous growth of MTI was not affected
by anti-EGF IgG treatment. The failure of the antibody to
affect the growth of MTI cells growing subcutaneously is
unlikely to be due to limited access of antibody delivered to
the subcutaneous site. If EGF exerted a direct effect on
intraperitoneal growth ofMTI, then the differing results may
be explained by the relatively large numbers of cells which
were necesary for subcutaneous growth of the tumour
(which developed as a single discrete nodule); it is possible
that the large inoculum enabled establishment of a microen-
vironment which facilitated proliferation, possibly by an
autocrine mechanism involving growth factors produced by
the MTI cells themselves. Alternatively, if EGF exerted an
indirect effect on intraperitoneal growth of MTI, the
different response of the subcutaneous tumour to antibody
treatment may be accounted for by the requirement for EGF
to promote the formation of an inflammatory environment
within the peritoneal cavity.
Extensive studies examining the effect of anti-human EGF
receptor antibodies (which do not recognise murine EGF
receptors) on the growth of human tumours grown as xeno-
grafts in nude mice have indicated their growth-inhibitory
potential, Particulary when used in combination with
cytotoxic drugs (Baselga el al., 1993). The involvement of
host-derived EGF in facilitating establishment of micro-
colonies of MTI tumour cells may indicate further new
directions for carcinoma therapy. Although the results of this
study demonstrate an anti-carcinoma effect of anti-EGF
antibody, such an antibody approach has no therapeutic
value for it induces severe kidney damage. Although EGF
receptor antibodies have been administered as single doses toHOST-DERIVED EGF AND TUMOUR GROWTH 269
patients for tumour imaging (Divgi et al., 1991), the long-
term toxicity of repeated administration of such antibodies to
human subjects remains to be determined (see Baselga et al.,
1993).
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